GPR56 Antibody

What is GPR56 and what cell types express this receptor?

GPR56 is a member of the adhesion G-protein-coupled receptor family that plays important roles in cell adhesion, brain development, and immune function. It is predominantly expressed in the brain and heart, but significant expression has also been found in immune cells, particularly natural killer (NK) cells . In pathological conditions, GPR56 is upregulated in colorectal tumors compared to normal tissues and is located on the surface of colorectal cancer cells . GPR56 expression has been associated with microsatellite stable tumors, those negative for the CpG methylator phenotype, and tumors showing chromosomal instability . Expression analyses of normal tissues have shown highest GPR56 levels in specific areas of the brain, kidney, pancreas, and thyroid, though at lower levels compared to tumors .

What applications can GPR56 antibodies be used for?

GPR56 antibodies have been validated for multiple research applications. According to the search results, common applications include:

• Western blot (WB) for detection of GPR56 in cell and tissue lysates

• Flow cytometry for cell surface detection of GPR56

• Immunoprecipitation (IP) for isolating GPR56 protein complexes

• Immunofluorescence (IF) for visualizing GPR56 localization

• Enzyme-linked immunosorbent assay (ELISA) for quantitative detection

• Simple Western™ analysis for automated protein detection

Researchers should note that optimal antibody dilutions need to be determined by each laboratory for each specific application .

What are the expected band sizes when detecting GPR56 by Western blot?

When detecting GPR56 by Western blot, researchers should be aware that different band sizes have been reported, which may reflect different post-translational modifications or processing of the receptor. According to the search results:

• Using the R&D Systems Human GPR56 Antibody (AF4634), a specific band was detected at approximately 65 kDa in lysates of human brain cortex and hippocampus tissues .

• In Simple Western™ analysis, the same antibody detected GPR56 at approximately 116 kDa in human brain motor cortex tissue and SK-BR-3 human breast cancer cell line .

These size differences could be attributed to differential glycosylation, proteolytic processing, or other post-translational modifications of GPR56 in different tissues or experimental conditions.

How should I validate the specificity of a GPR56 antibody?

Proper validation of GPR56 antibody specificity is critical for reliable research results. Recommended validation approaches include:

• Compare staining/detection patterns between the anti-GPR56 antibody and control antibodies (isotype controls) as demonstrated in flow cytometry experiments with human peripheral blood lymphocytes .

• Test multiple tissue types known to express varying levels of GPR56, such as human brain (cortex, hippocampus, motor cortex) and cancer cell lines like SK-BR-3 .

• Perform knockout/knockdown validation where GPR56 expression is genetically reduced or eliminated to confirm signal specificity.

• Cross-validate detection using multiple detection methods (e.g., Western blot, flow cytometry, immunofluorescence) to ensure consistent results across platforms.

• For therapeutic development purposes, test binding affinity using cell-based fluorescence binding assays as described for mAb 10C7 .

How do anti-GPR56 monoclonal antibodies affect GPR56-mediated signaling?

Anti-GPR56 monoclonal antibodies can modulate GPR56-mediated signaling pathways. Research has shown that a specific monoclonal antibody (mAb 10C7) potentiates GPR56-mediated intracellular signaling . When GPR56 is overexpressed in 293T cells, it leads to increased phosphorylation of Src, Fak, and paxillin adhesion proteins, as well as activation of the Gα12/13-RhoA-mediated serum response factor (SRF) pathway . Treatment with the anti-GPR56 mAb 10C7 further enhanced Src-Fak phosphorylation, RhoA-SRF signaling, and cell adhesion .

This demonstrates that certain GPR56 antibodies can serve not only as detection tools but also as functional modulators of GPR56 signaling. This property could be exploited for therapeutic development or as research tools to study GPR56 signaling mechanisms.

What is known about the epitope mapping of anti-GPR56 antibodies?

Epitope mapping of anti-GPR56 antibodies provides critical information about their binding characteristics and potential functional effects. The mAb 10C7, directed against the extracellular domain (ECD) of GPR56, has been studied in detail:

• Its binding site was mapped to the GAIN domain of GPR56, which mediates membrane-proximal autoproteolytic cleavage of the ECD .

• Further characterization revealed that the epitope is specifically located at the C-terminal end of the extracellular domain, proximal to the GPCR proteolysis site .

Understanding the precise epitope location is crucial because:

• It explains how the antibody might affect receptor function (e.g., by interfering with ligand binding or receptor processing)

• It determines whether the antibody can recognize both cleaved and uncleaved forms of GPR56

• It informs the design of therapeutic antibodies or antibody-drug conjugates targeting specific functional domains of GPR56

How can GPR56 antibodies be developed into antibody-drug conjugates for cancer therapy?

GPR56 antibodies show promising potential for development into antibody-drug conjugates (ADCs) for cancer therapy, particularly for colorectal cancer. A study described the development of a duocarmycin-based ADC using the anti-GPR56 mAb 10C7 . The development process included:

• Generation and characterization of a high-affinity antibody (10C7) targeting the extracellular domain of GPR56 .

• Confirmation that the antibody co-internalizes with GPR56 and traffics to the lysosomes of colorectal cancer cells, which is critical for efficient ADC payload release .

• Conjugation of the antibody to duocarmycin (a DNA minor-groove-binding, alkylating payload) via a protease-cleavable linker .

• Testing the ADC in colorectal cancer cell lines and tumor organoids with different levels of GPR56 expression, showing selective cytotoxicity at low nanomolar concentrations in a GPR56-dependent manner .

• Demonstration of significant antitumor efficacy against GPR56-expressing patient-derived xenograft models of colorectal cancer .

This research provides a rationale for developing GPR56-targeted ADCs to potentially treat a large fraction of colorectal cancer patients, particularly those with non-MSI-H tumors .

What are the technical considerations for conjugating GPR56 antibodies to create ADCs?

Creating effective antibody-drug conjugates with GPR56 antibodies requires careful consideration of several technical aspects:

• Conjugation method: As described in the research, cysteine-based conjugation can be employed, involving partial reduction of the interchain disulfide bonds of the antibodies to generate reactive cysteine thiol groups, followed by conjugation of the linker-payload .

• Linker-payload selection: The specific linker-payload (mc-vc-PAB-DMEA(PEG2)-Duocarmycin SA) was used in the GPR56 ADC development, but researchers might consider other payloads such as pyrrolobenzodiazepines for potentially improved efficacy .

• Drug-antibody ratio (DAR): The developed GPR56 ADC had an average DAR of 3.54, which is an important parameter affecting both efficacy and safety of the ADC .

• Quality control: ADCs should be analyzed for purity (e.g., by SDS-PAGE), aggregation (size exclusion chromatography), and drug-antibody ratio (hydrophobic interaction chromatography) .

• Future improvements: Strategies for enhancing ADC efficacy include affinity maturation of the antibody, increasing the DAR, and conjugation to more potent payloads .

Why might I detect different molecular weights of GPR56 in Western blot experiments?

Detecting different molecular weights of GPR56 in Western blot experiments is a common observation that can be explained by several biological and technical factors:

• Autoproteolytic processing: GPR56 undergoes autoproteolytic cleavage at the GAIN domain, resulting in an N-terminal fragment (NTF) and a C-terminal fragment (CTF) that remain non-covalently associated . Depending on the antibody epitope, you may detect either the full-length receptor or specific fragments.

• Post-translational modifications: Differential glycosylation patterns can significantly affect the apparent molecular weight of GPR56. The same antibody (AF4634) detected GPR56 at approximately 65 kDa in human brain tissue but at approximately 116 kDa in Simple Western™ analysis .

• Experimental conditions: The reducing conditions used in Western blot can affect the observed molecular weight. The R&D Systems experiments specifically noted that detection was conducted "under reducing conditions and using Immunoblot Buffer Group 8" .

• Cell/tissue type: Different cell types or tissues may express different GPR56 isoforms or process the receptor differently, as evidenced by the detection of different band sizes in brain tissue versus cancer cell lines .

To address these variations, it is advisable to include positive controls of known molecular weight and to document the specific experimental conditions used when reporting results.

What are the optimal conditions for detecting GPR56 by flow cytometry?

For optimal detection of GPR56 by flow cytometry, consider the following protocol elements based on the search results:

• Antibody selection: Use a validated anti-GPR56 antibody such as the Sheep Anti-Human GPR56 Affinity-purified Polyclonal Antibody (Catalog # AF4634) .

• Appropriate controls: Include relevant control antibodies, such as isotype controls (e.g., Catalog # 5-001-A) to establish baseline and determine specific staining .

• Secondary antibody: Use a fluorophore-conjugated secondary antibody appropriate for your primary antibody, such as Phycoerythrin-conjugated Anti-Sheep IgG Secondary Antibody .

• Co-staining markers: Consider co-staining with lineage markers (such as CD56 for NK cells) to identify specific cell populations expressing GPR56 .

• Protocol reference: Follow established protocols for staining membrane-associated proteins, such as those provided by antibody manufacturers .

• Sample preparation: Ensure proper single-cell suspensions with minimal cell clumping and appropriate blocking of Fc receptors to reduce non-specific binding.

• Instrument settings: Calibrate flow cytometer and set compensation properly, especially when using multiple fluorophores.

How do I determine if my GPR56 antibody has functional effects on receptor signaling?

To determine if a GPR56 antibody has functional effects on receptor signaling, you could implement the following experimental approaches:

• Phosphorylation assays: Measure changes in phosphorylation of downstream signaling molecules such as Src, Fak, and paxillin after antibody treatment. This approach was used to demonstrate that mAb 10C7 potentiated GPR56-mediated signaling .

• RhoA activation assays: Assess activation of RhoA, a downstream effector of GPR56 signaling through Gα12/13, using pull-down assays with the Rho-binding domain of rhotekin .

• Reporter gene assays: Utilize serum response factor (SRF) reporter assays to measure activation of the Gα12/13-RhoA-SRF pathway following antibody treatment .

• Cell adhesion assays: Quantify changes in cell adhesion properties, as GPR56 is involved in cell adhesion, and antibodies like mAb 10C7 have been shown to enhance GPR56-mediated cell adhesion .

• Receptor internalization studies: Investigate whether antibody binding triggers internalization of GPR56, which can affect signaling duration and intensity. This is particularly relevant for ADC development, as demonstrated with the GPR56 ADC .

• Comparison with known ligands: Compare antibody effects with those of known GPR56 ligands or agonists to determine if the antibody has agonistic, antagonistic, or allosteric modulator properties.

What are the potential off-target effects of GPR56-targeted therapies?

Understanding potential off-target effects is crucial for developing safe GPR56-targeted therapies such as antibody-drug conjugates. Based on the search results, several considerations should be addressed:

• Normal tissue expression: GPR56 is expressed in normal tissues including areas of the brain, kidney, pancreas, and thyroid, though at lower levels compared to tumors . This expression pattern could potentially lead to on-target/off-tumor effects.

• Blood-brain barrier protection: For targeted therapies using antibodies, the blood-brain barrier (BBB) may provide protection against adverse effects on brain tissue, as "mAbs generally do not cross the blood-brain barrier" .

• Immune cell effects: GPR56 expression on human natural killer (NK) cells, where it has been shown to inhibit effector functions during their inactive state, raises concerns about potential immunomodulatory effects of GPR56-targeted therapies .

• Comparative expression levels: The relative surface levels of GPR56 on immune cells versus tumor cells need to be assessed to understand the potential impact of GPR56-targeted therapies on the immune system .

• Surrogate models: Testing of a surrogate antibody that binds GPR56 in rodent models is needed to appropriately address potential systemic on-target effects .

These considerations highlight the need for comprehensive safety studies before advancing GPR56-targeted therapies to clinical trials.

How does GPR56 expression correlate with colorectal cancer subtypes?

The search results provide important insights into the correlation between GPR56 expression and colorectal cancer subtypes:

• Molecular subtypes: High GPR56 expression is associated with specific molecular characteristics in colorectal tumors: microsatellite stable (non-MSI-H), negative for the CpG island methylator phenotype (non-CIMP), and positive for chromosomal instability (CIN+) .

• Prognostic significance: GPR56 correlates with poor prognosis and survival in colorectal cancer patients .

• Therapeutic resistance: GPR56 has been associated with drug resistance in colorectal cancer, as demonstrated by several studies .

• Tumor growth promotion: GPR56 promotes tumor growth in mouse models of colorectal cancer .

These correlations suggest that GPR56-targeted therapies may be particularly beneficial for non-MSI-H colorectal tumors, which represent a large fraction of colorectal cancer cases. The association with specific molecular subtypes could help guide patient selection in future clinical trials of GPR56-targeted therapies.

What strategies can improve the efficacy of GPR56-targeted antibody-drug conjugates?

Several strategies have been proposed to enhance the efficacy of GPR56-targeted antibody-drug conjugates for cancer therapy:

• Antibody affinity maturation: Improving the binding affinity of the antibody to GPR56 could enhance target engagement and drug delivery .

• Increasing drug-antibody ratio (DAR): Higher DAR values could potentially deliver more cytotoxic payload to cancer cells, though this needs to be balanced against potential impacts on antibody stability and pharmacokinetics .

• More potent payloads: Conjugation to more potent cytotoxic agents, such as pyrrolobenzodiazepines, could increase the killing efficiency of GPR56 ADCs .

• Linker optimization: Developing improved linker technologies that ensure stability in circulation but efficient release in tumor cells could enhance the therapeutic window.

• Combination therapies: Exploring combinations with other therapeutic modalities, such as immune checkpoint inhibitors or conventional chemotherapy, might produce synergistic effects.

• Patient selection: Given the correlation between GPR56 expression and specific colorectal cancer subtypes, careful patient selection based on GPR56 expression levels and molecular characteristics could improve clinical outcomes.

These strategies represent active areas of research that could lead to the development of more effective GPR56-targeted therapies for colorectal cancer and potentially other tumor types with high GPR56 expression.

How can researchers address discrepancies in GPR56 molecular weight detection across different experimental platforms?

To address discrepancies in GPR56 molecular weight detection across different experimental platforms, researchers should consider implementing the following strategies:

• Document experimental conditions: Clearly specify the reducing or non-reducing conditions used in Western blot experiments, as this can significantly affect the observed molecular weight of GPR56 .

• Use multiple antibodies: Employ antibodies targeting different epitopes of GPR56 to distinguish between full-length receptor and processed fragments.

• Positive controls: Include recombinant GPR56 proteins of known molecular weight as positive controls in experiments.

• Deglycosylation experiments: Treat samples with glycosidases to remove N-linked and O-linked glycans, potentially reducing variability due to differential glycosylation.

• Cross-platform validation: Validate findings using multiple detection methods such as Western blot, Simple Western™, and mass spectrometry to get a more complete picture of GPR56 forms.

• Cell-specific controls: Include lysates from GPR56-knockout or overexpressing cells as controls to definitively identify specific GPR56 bands.

• Standardize sample preparation: Use consistent lysis buffers, protease inhibitors, and sample handling procedures across experiments to minimize technical variations.

By systematically addressing these factors, researchers can better interpret apparently discrepant results and develop a more comprehensive understanding of GPR56 processing and modifications in different cellular contexts.